The effect of oral administration of thyme honey on anemia and some cardiovascular risk factors in hemodialysis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201705266318N9

Enrollment

Registered

2017-07-01

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: Intervention group will use 33 grams of thyme honey on each morning shift on a daily bases for one month. Intervention 2: Control group: The control group will unde

Prevention

Intervention group: Intervention group will use 33 grams of thyme honey on each morning shift on a daily bases for one month.

Control group: The control group will undergo routine care.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Desire to participate and giving the written consent; treatment with hemodialysis 3 times a week for 3 hours or more per session and for more than 3 months; not being diagnosed with cancer; mental disability; liver failure and not being allergic to honey. Exclusion criteria: Hospitalization and changes in the patient's medications during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hemoglobin. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, hemoglobin is measured with Cell take E.	—

Secondary

Measure	Time frame
C- reactive protein. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, C-Reactivate protein is measured with bionik vial.;Glucose. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, glucose is measured with Pars test.;Hematocrit. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, hematocrit is measured with Cell take E.;Lipids. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, lipids are measured with Pars test.	—

Measure

Time frame

C- reactive protein. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, C-Reactivate protein is measured with bionik vial.;Glucose. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, glucose is measured with Pars test.;Hematocrit. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, hematocrit is measured with Cell take E.;Lipids. Timepoint: Before the intervention; one month after intervention. Method of measurement: In this study, lipids are measured with Pars test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Monir Nobahar

Semnan University of Medical Sciences

Nobahar43@semums.ac.ir; Nobahar43@yahoo.com+98 23 3365 4170

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026